Arnold Z Olali1, Qiuhu Shi2, Donald R Hoover3, Mariana Bucovsky4, Elizabeth Shane4, Michael T Yin4, Ryan D Ross5. 1. Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL, United States of America. 2. Department of Public Health, New York Medical College, Valhalla, NY, United States of America. 3. Department of Statistics and Institute for Health, Health Care Policy and Aging Research, Rutgers University, Piscataway, NJ, United States of America. 4. Columbia University Irving Medical Center, New York, NY, United States of America. 5. Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL, United States of America. Electronic address: Ryan_Ross@rush.edu.
Abstract
BACKGROUND: Bone mineral density (BMD) loss and fat gain is common in people living with HIV (PLWH), particularly after initiating combination antiretroviral therapy (cART). Given the close metabolic interaction between bone and fat, we tested the hypotheses that changes in bone-derived hormones are associated with fat accumulation and changes in fat-derived hormones are associated with BMD loss following cART initiation. METHODS: HIV-seropositive subjects (n = 15) initiating fixed dose cART of tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) underwent dual X-ray absorptiometry (DXA) assessment pre-cART and again 12-months post-cART initiation. DXA-derived measurements included BMD at the lumbar spine, femoral neck, total hip, and trochanter and the trunk and total fat. Serum undercarboxylated osteocalcin (ucOCN), sclerostin, lipocalin-2, leptin, and adiponectin were measured pre and post-cART. Spearman's rank-order correlations assessed the cross-sectional associations between hormones and bone and fat mass pre- and post-cART. Linear regression models adjusting for baseline bone or fat mass assessed the association between hormone change and BMD/fat changes following cART initiation. RESULTS: ucOCN (p = 0.04) and lipocalin-2 (p = 0.03) increased post-cART while sclerostin, leptin, and adiponectin remained unchanged. BMD significantly decreased post-cART at all skeletal sites. Trunk and total fat increased post-cART but not significantly, while weight and BMI remained unchanged. In models adjusting for baseline BMD and fat mass, change in ucOCN was negatively associated with change in trunk (p = 0.008) and total fat (p = 0.01) and the change in leptin was positively associated with change in total hip (p = 0.03) and trochanteric BMD (p = 0.02). CONCLUSION: The current study demonstrates bone-fat crosstalk in cART initiating PLWH.
BACKGROUND: Bone mineral density (BMD) loss and fat gain is common in people living with HIV (PLWH), particularly after initiating combination antiretroviral therapy (cART). Given the close metabolic interaction between bone and fat, we tested the hypotheses that changes in bone-derived hormones are associated with fat accumulation and changes in fat-derived hormones are associated with BMD loss following cART initiation. METHODS: HIV-seropositive subjects (n = 15) initiating fixed dose cART of tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) underwent dual X-ray absorptiometry (DXA) assessment pre-cART and again 12-months post-cART initiation. DXA-derived measurements included BMD at the lumbar spine, femoral neck, total hip, and trochanter and the trunk and total fat. Serum undercarboxylated osteocalcin (ucOCN), sclerostin, lipocalin-2, leptin, and adiponectin were measured pre and post-cART. Spearman's rank-order correlations assessed the cross-sectional associations between hormones and bone and fat mass pre- and post-cART. Linear regression models adjusting for baseline bone or fat mass assessed the association between hormone change and BMD/fat changes following cART initiation. RESULTS: ucOCN (p = 0.04) and lipocalin-2 (p = 0.03) increased post-cART while sclerostin, leptin, and adiponectin remained unchanged. BMD significantly decreased post-cART at all skeletal sites. Trunk and total fat increased post-cART but not significantly, while weight and BMI remained unchanged. In models adjusting for baseline BMD and fat mass, change in ucOCN was negatively associated with change in trunk (p = 0.008) and total fat (p = 0.01) and the change in leptin was positively associated with change in total hip (p = 0.03) and trochanteric BMD (p = 0.02). CONCLUSION: The current study demonstrates bone-fat crosstalk in cART initiating PLWH.
Authors: Grace A Lee; Derek D Mafong; Mustafa A Noor; Joan C Lo; Kathleen Mulligan; Jean-Marc Schwarz; Morris Schambelan; Carl Grunfeld Journal: J Acquir Immune Defic Syndr Date: 2004-05-01 Impact factor: 3.731
Authors: Daniel Cejka; Agnes Jäger-Lansky; Heidi Kieweg; Michael Weber; Christian Bieglmayer; Dominik G Haider; Danielle Diarra; Janina M Patsch; Franz Kainberger; Barbara Bohle; Martin Haas Journal: Nephrol Dial Transplant Date: 2011-05-25 Impact factor: 5.992
Authors: Kamil E Barbour; Joseph M Zmuda; Robert Boudreau; Elsa S Strotmeyer; Mara J Horwitz; Rhobert W Evans; Alka M Kanaya; Tamara B Harris; Douglas C Bauer; Jane A Cauley Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: Karin Amrein; Steven Amrein; Camilla Drexler; Hans Peter Dimai; Harald Dobnig; Klaus Pfeifer; Andreas Tomaschitz; Thomas R Pieber; Astrid Fahrleitner-Pammer Journal: J Clin Endocrinol Metab Date: 2011-10-12 Impact factor: 5.958
Authors: L Lenchik; T C Register; F C Hsu; K Lohman; B J Nicklas; B I Freedman; C D Langefeld; J J Carr; D W Bowden Journal: Bone Date: 2003-10 Impact factor: 4.398
Authors: Madhu N Rao; Morris Schambelan; Viva W Tai; Donald I Abrams; Hootan Khatami; Peter J Havel; Giorgos Sakkas; Kathleen Mulligan Journal: AIDS Res Treat Date: 2012-08-27
Authors: Arnold Z Olali; Anjali Sharma; Qiuhu Shi; Donald R Hoover; Kathleen M Weber; Audrey L French; Heather S McKay; Phyllis C Tien; Lena Al-Harthi; Michael T Yin; Ryan D Ross Journal: J Acquir Immune Defic Syndr Date: 2021-04-15 Impact factor: 3.771